Cargando…
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, an...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324085/ https://www.ncbi.nlm.nih.gov/pubmed/35385124 http://dx.doi.org/10.1002/cncr.34222 |